Iovance Biotherapeutics Inc

-0.22 (-3.83%)
6:08:26 PM EDT: $6.31 +0.78 (+14.11%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.24B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.22 Million
Adjusted EPS-$0.57
See more estimates
10-Day MA$6.18
50-Day MA$7.06
200-Day MA$8.88
See more pivots

Iovance Biotherapeutics Inc Stock, NASDAQ:IOVA

825 Industrial Road, Suite 400, San Carlos, California 94070
United States of America
Phone: +1.650.260.7120
Number of Employees: 503


Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.